ClinicalTrials.gov
public full text
Public Domain
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM
GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). The aims of this placebo controlled study are to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1070806 in obese subjects with Type 2 diabetes mellitus (T2DM), and to gain a better understanding of the mechanism by which GSK1070806 exerts its therapeutic effects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6#874513
- Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus#883677
- A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus#152590
- LEVEL OF INTERLEUKIN-6 IN OBESE PEOPLE WITH AND WITHOUT INSULIN RESISTANCE#930355
- Interleukin-1 Receptor Antagonist and Insulin Sensitivity#827059
Record · ID 843977
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive